Ribbon Communications And 2 Other Stocks Under $3 Insiders Are Aggressively Buying
Ribbon Communications And 2 Other Stocks Under $3 Insiders Are Aggressively Buying
Ribbon Communications和其他两只低于3美元的股票内部人士正在积极买入
The Dow Jones jumped more than 500 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
道琼斯指数周五上涨了500多点。当内部人士购买或出售股票时，这表明他们对公司前景的信心或担忧。对便士股感兴趣的投资者和交易者可以将其视为其整体投资或交易决策中的一个因素。
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
以下是近期一些值得注意的细价股内幕交易。欲了解更多，请查看 本辛加的内幕交易 平台。
Ribbon Communications
丝带通讯
- The Trade: Ribbon Communications Inc. (NASDAQ:RBBN) Preseident and CEO William Bruce McClelland acquired a total 10,000 shares an average price of $2.60. To acquire these shares, it cost around $26 thousand. The company's EVP and CFO also purchased the company's shares.
- What's Happening: Ribbon Comms posted a narrower-than-expected quarterly loss.
- What Ribbon Communications Does: Ribbon Communications Inc provides network solutions primarily to telecommunications, wireless and cable service providers worldwide.
- 交易： 丽邦通讯公司 （纳斯达克股票代码：RBBN）总裁兼首席执行官威廉·布鲁斯·麦克莱兰 共收购了 10,000 股股票 平均价格为2.60美元。收购这些股票的成本约为2.6万美元。该公司的执行副总裁兼首席财务官也购买了该公司的股票。
- 发生了什么： Ribon Comms公布的季度亏损低于预期。
- Ribbon Communicat Ribbon Communications Inc 主要为全球的电信、无线和有线电视服务提供商提供网络解决方案。
TCR2 Therapeutics
TCR2 疗法
- The Trade: TCR2 Therapeutics Inc. (NASDAQ:TCRR) 10% owner Tang Capital Partners LP acquired a total of 289,577 shares at an average price of $1.89. The insider spent around $547.94 thousand to buy those shares.
- What's Happening: TCR2 Therapeutics posted a wider Q4 loss.
- What TCR2 Therapeutics Does: TCR2 Therapeutics Inc is a clinical-stage cell therapy company. It is engaged in developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors by powering the T cell receptor (TCR) with its proprietary, first-in-class TCR Fusion Construct T cells (TRuC-T cells).
- 这笔交易: TCR2 Therapeutics Inc （纳斯达克股票代码：TCRR）10% 所有者唐资本合伙人有限责任公司 共收购了289,577股股票 平均价格为1.89美元。内部人士花费了约547.94万美元购买这些股票。
- 发生了什么: TCR2 Therapeutics公布了更广泛的第四季度亏损。
- TCR2 Therapeutics 做什么: TCR2 Therapeutics Inc 是一家临床阶段的细胞疗法公司。它利用其专有的、同类首创的TCR Fusion Construct T细胞（truc-T细胞）为T细胞受体（TCR）提供动力，为患有实体瘤的癌症患者开发一系列新的T细胞疗法。
Creek Road Miners
克里克路矿工
- The Trade: Creek Road Miners, Inc. (OTC:CRKR) Director Michael Martin Breen acquired a total of 1,134,683 shares at an average price of $0.12. To acquire these shares, it cost around $138.11 thousand.
- What's Happening: Creek Road Miners, Inc. completed merger with Prairie Operating Co., LLC, establishing Prairie Operating Co.
- What Creek Road Miners Does: Creek Road Miners Inc develops and operates bitcoin mining scaled-up facilities using natural gas to power the operations. It generates substantially all its revenue through cryptocurrency, which it earns through mining activities.
- 这笔交易: Creek Road Miners, (OTC: CRKR) 导演迈克尔·马丁·布雷恩 共收购了 1,134,683 股股票 平均价格为0.12美元。收购这些股票的成本约为138.11万美元。
- 发生了什么: Creek Road Miners, Inc. 完成了与 Prairie Operinating Co., LLC 的合并，成立了 Pra
- 克里克路矿工在做什么: Creek Road Miners Inc开发和运营比特币采矿规模化设施，使用天然气为运营提供动力。它几乎所有的收入都是通过加密货币产生的，而加密货币是通过采矿活动获得的。
Check This Out: Top 5 Defensive Stocks That May Implode In Q2
看看这个： 第二季度可能暴跌的五大防御性股票
Don't forget to check out our premarket coverage here
别忘了在这里查看我们的上市前报道